TargetMol

T521

Product Code:
 
TAR-T28904
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T28904-1mg1mg£400.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28904-5mg5mg£852.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28904-10mg10mg£1,107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28904-25mg25mg£1,637.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28904-50mg50mg£2,183.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T28904-100mg100mg£2,922.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
T521 is a novel specific inhibitor of the PBD of Plk1 with no inhibiting effect of Plk2-3.
CAS:
891020-54-5
Formula:
C17H14FNO5S2
Molecular Weight:
395.42
Pathway:
Cell Cycle/Checkpoint
Purity:
0.98
SMILES:
CCS(=O)(=O)c1oc(nc1S(=O)(=O)c1ccccc1)-c1ccc(F)cc1
Target:
PLK

References

1. Archambault V, Normandin K. Several inhibitors of the Plk1 Polo-Box Domain turn out to be non-specific protein alkylators. Cell Cycle. 2017 May 19:1-5. doi: 10.1080/15384101.2017.1325043. [Epub ahead of print] PubMed PMID: 28521657. 2. Chen Y, Zhang J, Li D, Jiang J, Wang Y, Si S. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain. Oncotarget. 2017 Jan 3;8(1):1234-1246. doi: 10.18632/oncotarget.13603. PubMed PMID: 27902479; PubMed Central PMCID: PMC5352051. 3. Ben Said M, Abbassi MS, Bianchini V, Sghaier S, Cremonesi P, Roman? A, Gualdi V, Hassen A, Luini MV. Genetic characterization and antimicrobial resistance of Staphylococcus aureus isolated from bovine milk in Tunisia. Lett Appl Microbiol. 2016 Dec;63(6):473-481. doi: 10.1111/lam.12672. Epub 2016 Nov 2. PubMed PMID: 27657910. 4. Birmingham BK, Bujac SR, Elsby R, Azumaya CT, Wei C, Chen Y, Mosqueda-Garcia R, Ambrose HJ. Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect? Eur J Clin Pharmacol. 2015 Mar;71(3):341-55. doi: 10.1007/s00228-014-1801-z. Epub 2015 Feb 12. PubMed PMID: 25673568.